NCT02636569 2026-01-21
Topical Chemoprevention of Skin Cancer Biomarkers
University of Alabama at Birmingham
Phase 2 Completed
Clinical Trials
13 trialsNCT02406014 2025-02-24
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
LEO Pharma
Phase 4 Completed
NCT05387525 2025-02-11
AKtive
Almirall, S.A.
Phase 4 Active not recruiting
NCT04552327 2024-03-05
KOHDIAK
Infectopharm Arzneimittel GmbH
Phase 3 Completed
NCT00777127 2022-02-07
LEIDA
Viatris Inc.
Phase 4 Completed
NCT01453179 2022-02-07
LEIDA 2
Viatris Inc.
Phase 4 Completed
NCT01962987 2020-07-20
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
Actavis Inc.
Phase 3 Completed
NCT03826550 2019-02-01
Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis
Encube Ethicals Pvt. Ltd.
Phase 3 Completed
NCT02611804 2017-05-05
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
Teva Pharmaceuticals USA
Phase 3 Completed
NCT01935531 2016-03-31
Effects of Topical Diclofenac on Tumor Metabolism
University Hospital Regensburg
Phase 4 Completed
NCT01358045 2015-01-13
Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma
Maastricht University Medical Center
Phase 2 Completed
NCT01742663 2014-01-22
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 1 Completed
NCT00204542 2011-08-19
Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head
University Hospital Tuebingen
Phase 4 Completed